Skip to main content

Table 2 Mean and standard deviation of the 3 US outcome measures in the CTS patients cohort stratified according to the severity of their NCS before and after treatment

From: Ultrasound assessment of the median nerve: a biomarker that can help in setting a treat to target approach tailored for carpal tunnel syndrome patients

Median Nerve

Nerve Conduction Testing

Baseline

1-wk post- management

1-month post management

6-month post- management

P-value

Cross Sectional Area (CSA)

Mild

11.34 (0.16)

10.92 (0.2)

9.81 (0.15)

9.78 (0.3)

<0.001*

Moderate

14.4 (0.5)

15.4 (0.4)

11.1 (0.3)

11.09 (0.4)

<0.001*

Severe

18.91 (0.7)

18.87 (0.6)

17.43 (0.7)

16.41 (0.5)

<0.001*

Flattening Ratio

Mild

2.52 (0.1)

2.33 (0.3)

2.2 (0.4)

2.02 (0.3)

<0.001*

Moderate

2.84 (0.02)

2.6 (0.06)

2.47 (0.04)

2.42 (0.03)

<0.001*

Severe

2.9 (0.2)

2.89 (0.4)

2.88 (0.3)

2.78 (0.2)

<0.001*

Power Doppler

Mild

1.28 (0.6)

0.2 (0.4)

0.04 (0.2)

0.09 (0.3)

<0.001*

Moderate

2.1 (0.5)

1.08 (0.6)

0.49 (0.5)

0.05 (0.2)

<0.001*

Severe

0.40 (0.5)

0.4 (0.5)

0.33 (0.5)

0.30 (0.46)

<0.001*

  1. *: P< 0.01.